Winton Group’s AIM ImmunoTech AIM Stock Holding History

Winton Group’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-157	Closed	-$14K	–	1209
2021 Q4	$14K	Sell	157 -669	-81%	-$103K	﹤0.01%	989
2021 Q3	$167K	Buy	826 +277	+50%	+$55.9K	0.01%	1258
2021 Q2	$118K	Buy	+549	New	+$118K	0.01%	1379

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Winton Group's AIM Position: Q1 2022 in Review

Winton Group sold out of AIM ImmunoTech (AIM) in Q1 2022, closing a stake of 157 shares — an estimated $14K sold.

Winton Group first reported a position in AIM in Q2 2021 and held it in 3 quarters. The position peaked at $167K in Q3 2021. 35 funds tracked by Wall St. Rank hold AIM as of Q1 2022.

Winton Group reported no remaining AIM ImmunoTech position as of Q1 2022 after selling out during the quarter.
Winton Group sold 157 AIM ImmunoTech shares in Q1 2022, an estimated $14K.
Winton Group first reported a position in AIM ImmunoTech in Q2 2021 and held it in 3 quarters.
Winton Group's AIM ImmunoTech position peaked at $167K in Q3 2021.
35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.